Quantcast
Home > Quotes > CYTR
CYTR

CytRx Corporation Common Stock (CYTR) Quote & Summary Data

$1.1
*  
0.03
2.8%
Get CYTR Alerts
*Delayed - data as of Aug. 17, 2018  -  Find a broker to begin trading CYTR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
4.5
Today's High / Low
$ 1.12 / $ 1.07
Share Volume
56,238
50 Day Avg. Daily Volume
149,016
Previous Close
$ 1.07
52 Week High / Low
$ 3.8042 / $ 1.05
Market Cap
37,001,251
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.34

Intraday Chart

Shares Traded

Share Volume:
56,238
50 Day Avg. Daily Volume:
149,016

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.60

Trading Range

The current last sale of $1.10 is 4.76% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.12 $ 3.8042
 Low: $ 1.07 $ 1.05

Company Description (as filed with the SEC)

We are a biopharmaceutical research and development company specializing in oncology. Our focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. Since 2008, we have worked to develop aldoxorubicin. In July 2017 we entered into an exclusive worldwide license under which NantCell, Inc. took over development of aldoxorubicin, invested in our common stock and agreed to make future milestone and royalty payments upon the successful development and commercialization of aldoxorubicin. We are now actively pursuing new anti-cancer compounds through our drug discovery and research operation at our laboratory facilities in Freiburg, Germany led by Felix Kratz, Ph.D., Vice President of Drug Discovery and inventor of aldoxorubicin. We are a Delaware corporation, incorporated in 1985.  ... More ...  


Risk Grade

Where does CYTR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.07
Open Date:
Aug. 17, 2018
Close Price:
$ 1.10
Close Date:
Aug. 17, 2018

Consensus Recommendation

Analyst Info